SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2977)12/6/2013 2:59:50 AM
From: scaram(o)uche  Respond to of 3202
 
re. rux combo study...... panobinostat extends PFS, multiple myeloma.....

novartis.com

As usual, link from Andy Biotech of twitter.



To: scaram(o)uche who wrote (2977)12/9/2013 12:50:13 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 3202
 
>> early efficacy, panobinostat combo, to the presented at meeting <<

novartis.medicalcongressposters.com

Unfortunately, there's no fibrosis data. Some patients from all dose escalation cohorts achieved 100% reduction in spleen size (palpation).... including all of them from the 25 TIW QOW/15 BID cohort.

(Link from a guy who celebrates when a cancer vaccine trial does not meet initial objectives.)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News